SUMMARY
analgesia) and with approximately the same duration of the first stage served as controls to assess any possible effect of alfentanil on the newborn.
Clinical management
Before inserting the extradural catheter (at the L3-4 space) a vaginal examination was carried out to obtain a reference Bishop score (Bishop, 1964) . Intrauterine pressure was monitored subsequently in 10 of the 16 patients (fetal monitoring intrauterine pressure kit, Hewlett-Packard 14099C, connected to a quartz transducer, Hewlett-Packard model 1290A). Uterine activity was expressed in Montevideo Units (the sum of the amplitudes (in mm Hg) of the contractions occurring during a 10-min period (CaldeiroBarcia and Poseiro, I960)).
A loading dose of alfentanil 30 ng kg~l diluted in saline to a total volume of 10 ml was injected to the extradural space when the parturient first asked for pain relief. This injection was immediately followed by a continuous infusion of 30 ug kg" 1 hr 1 . Top-up doses (30 ug kg-1 ) were given when deemed necessary and 0.2 % bupivacaine 10 ml was administered when the analgesia with alfentanil alone became inadequate. The infusion of alfentanil to the extradural space was stopped at the beginning of the second stage of labour. No further drugs were administered thereafter.
Arterial pressure, heart rate and ventilation rate were measured every 5 min for 30 min and, thereafter, at 15-min intervals or when clinically indicated. Maternal Pa co was measured in only four patients because of the inconvenience of arterial blood sampling in this setting.
Assessment of pain
The severity of pain was assessed every 5 min during the first 30 min, and at 15-min intervals thereafter, using a numerical rating scale 0-10 (0 = no pain at all, 10 = worst possible pain). Recurrence of pain was considered significant when the new pain score was equal to or greater than 50% of the initial pain score. At that moment, a new bimanual vaginal examination was carried out to obtain information regarding the descent of the fetal head (ischial spine = 0) and the rate of cervical dilatation (table II) .
Assessment of the newborn
The newborn infants were assessed using the Apgar score at 1, 3, 5 and 10 min and the Amiel-Tison score at 15-30 min of life (AmielTison, Barrier and Shnider, 1982) . The same neurobehavioural tests were performed on the 16 newborns which served as controls.
Comparisons between the groups were analysed using the Kruskal-Wallis one-way analysis of variance. In six patients, maternal blood samples were taken at birth, together with arterial and venous blood samples from the umbilical cord to permit the measurement of alfentanil concentration (radioimmunoassay).
RESULTS

Patient characteristics
The two groups were comparable with regard to maternal age and the duration of gestation (table I). The higher mean Bishop score in the control group can explain the shorter total duration of labour (Friedman et al., 1966) .
Pain scores
The mean initial pain score was somewhat higher than we usually observe and this was probably because of the score of 9 given by two patients.
Pain relief was excellent within less than 5 min in all patients and remained acceptable for 2-4.5 h ( fig. 1) .
No correlation could be found between the recurrence of pain (as denned above) and the degree of cervical dilatation, nor with the descent of the fetal head. However, recurrence of pain did coincide with an increase in uterine activity as expressed by the increase in Montevideo Units (table II) . Satisfactory pain relief could be maintained in 11 of the 16 patients by injecting additional doses of alfentanil. Such supplements of alfentanil only helped when given early in labour; they did not provide adequate analgesia in the latter part of stage I. Five patients required supplements of extradural bupivacaine.
Alfentanil requirements
The wide range observed in total dose is explained by both considerable differences in the duration of the infusions and in the body weight of the patients (50-105 kg), and the several supplementary doses given to some patients (table  III) .
Maternal and neonatal plasma concentrations of alfentanil at birth
No correlation was found between the duration of stage II-the interval during which no alfentanil was given-and the neonatal plasma concentrations of alfentanil. The umbilical vein: umbilical artery ratio of alfentanil was greater than 1, denoting fetal uptake or metabolism, or both (table IV) .
Clinical effects and side-effects
Drowsiness was reported by almost half the patients and occurred within 1-2 min of the injection (table V) . However, cerebral cognitive functions remained normal throughout labour. Dizziness occurred in three patients but only within the first 15 min of the injection. Itching, confined to the abdomen and legs, was reported by almost all patients, but elicited no spontaneous complaints. The incidence of nausea, excluding one patient receiving PGF a a, was 27%. No urinary retention was observed in 10 patients; information regarding the other six patients was unavailable. Hypotension, defined as a decrease in systolic arterial pressure of greater than 10%, did not occur. Ventilation rate decreased significantly from preinjection values, but this could be attributed to the effective analgesia and was never less than 15 b.p.m. In four patients, arterial blood samples, drawn when analgesia was complete, revealed P*co, values between 4.3 and 4.7 kPawithin the normal range for the parturient.
Evaluation of the neonate
As expected, theoretically, the duration of stage II was not prolonged in the alfentanil group compared with the control group. All the newborn infants had Apgar scores of 7 or more at 1 min (table VI). One baby in the control group had Apgar scores of 1, 3 and 5 at 1, 5 and 10 min and this accounted for the lower mean Apgar score in the control group. Umbilical arterial and venous pH values were comparable in both groups.
The total score on the neurological part of the Amiel-Tison test was significantly lower in the alfentanil group. This resulted from a lower score for passive (6.07) and active tone (5.75) than those recorded in the control group (passive: 7.31; active: 7.63). Further evaluation of the neonates by the paediatrician did not denote any abnormal feeding habits nor behavioural changes. 
DISCUSSION
The continuous extradural infusion of alfentanil was chosen for conduction analgesia during labour because of the short elimination half-life of alfentanil (Bower and Hull, 1982) , and on account of the short duration of action of a single injection of the drug (preliminary trial). These facts, together with the low umbilical cord: maternal vein ratio of 0.3 (Bonnardot, 1983) , led us to believe that the administration of additional doses, when required, would not increase the likelihood of neonatal ventilatory depression. Excellent pain relief was invariably obtained within 5 min after the injection of the loading dose of alfentanil; its high lipid solubility favoured rapid penetration of the dura. However, vascular uptake and transport via the posterior radicular artery or excretion through the arachnoid granulations in the dural cuff regions, or both, are important coexisting mechanisms (Cousins and Mather, 1984) .
Two characteristics of the pattern of pain relief in this study were of interest. First, no relationship could be found between the recurrence of pain and the position of the presenting part, or with the degree of cervical dilatation. This eliminated the possibility that recurrent abdominal (not perineal) pain, could be caused by central pain transmission via non-blocked nerves. On the other hand, there was a positive correlation, with an increase in Montevideo units or, in other words, with an increase in the contractile force of the uterus.
Second, it was noted that the incremental doses resulted in transient improvements in analgesia when given fairly early in labour, and not at all when given late in the first stage of labour. The same phenomenon was seen in the preliminary trial when the loading dose was given late in stage one; pain relief remained inadequate even when alfentanil 90 ug kg" 1 was given. This indicated that there is an inherent maximal analgesic capacity for extradurally administered alfentanil; thus, when uterine activity exceeds a certain limit in any individual patient, the administration of alfentanil, in whatever dose, will not result in adequate pain relief. Other studies (Carrie, O'Sullivan and Seegobin, 1981; Justins, Francis and Houlton, 1982; Justins, Knott and Luthman, 1983) demonstrated invariably the poor efficacy of extradural opioids during late stage I and during 8.56 (7-10) 9.60 (8-10) 9.80 (9-10) 7.32 (7.19-7.39) 7.25 (7.12-7.38) 6.07 ±0.25**** 5.75 ±0.52*** 5.07±0.18 5.87±0.13 22.92 ±0.68**** the second stage of labour. However, as supplementary doses were not administered, the possibility remained that an inadequate dose of opioid had been given in the first place. Our findings refute this possibility. It has been established that extradurally administered opioids exert their analgesic effect through a direct action upon the dorsal column and not centrally through intrathecal spread or vascular absorption (Kitahata and Collins, 1981; Yaksh, 1981) . Side-effects, however, are caused by the systemic absorption of the opioid. The rapid onset of such effects seemed to indicate a relatively rapid uptake of the drug via the extradural venous plexus.
Sedation was found to occur even before the onset of analgesia and to last throughout the period of the continuous infusion of alfentanil, although this effect was less apparent as analgesia became less complete. The lack of impairment of maternal cerebral function and the absence of complaints from the patients made us believe this side-effect was readily acceptable.
The high incidence of nausea and vomiting was disappointing and probably resulted from the direct effect of alfentanil on the area postrema in the floor of the fourth ventricle. In two patients, small doses of naloxone were administered to abolish the vomiting. As analgesia remained unaffected, this observation supports the hypothesis that the analgesia attributable to alfentanil results from an extradural, and not a central, site of action.
Itching has been reported to be frequent in parturient women (Scott, Bowen and Cartwright, 1980) . Mild pruritis was reported by 15 of the 16 patients in this study, but only on direct questioning. This sensation was confined to the abdomen and legs and was not consistent with the usual finding of most severe itching in the palate and the face (Yaksh, 1981) . Facial itching occurred in two patients immediately after the administration of a "top-up" dose.
Although adequate Apgar scores were found in the alfentanil group, the Amiel-Tison test clearly demonstrated neonatal hypotonia. As this was not reflected by the Apgar score, the evaluation of the effects of intrathecal and extradural opioids during labour should include the more sensitive neurobehavioural tests. Neonatal hypotonia constituted one of the major, if not the major, drawback of the use of alfentanil as it could lead to serious problems if other compromising factors were present.
The failure of opioid analgesia during the late stage I and stage II of labour could be caused by the transmission of pain via high-threshold neurones in lamina I which do not project on deeper laminae, but directly into the spinothalamic tract, thus bypassing the opioid u-receptors concentrated in the substantia gelatinosa (Bowsher, 1978; Yaksh, 1981) .
Alternatively, the observation that such different products as serotonin (Yaksh, 1978) , baclofen (Yaksh, 1978) and midazolam (Whitwam, 1983) can produce spinal analgesia, suggests that there are definite spinal systems mediating nociception, on which opioids cannot exert any influence.
It may be that "selective spinal analgesia" during labour is "too selective" and that a combination of an opioid with a local anaesthetic agent will be necessary.
